Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Solvonis Therapeutics plc is a clinical-stage biopharmaceutical company dedicated to developing novel medicines for addiction and mental health disorders, targeting high-burden neuropsychiatric conditions with significant unmet needs. Headquartered in London, the company advances a differentiated pipeline of repurposed and novel compounds, primarily focusing on Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD), which affect over 80 million people in the UK, US, and EU4. Its lead asset, SVN-001, is in Phase 3 trials for severe AUD in Europe and the UK, while SVN-002 prepares for Phase 2b in the US for moderate to severe AUD; a preclinical PTSD program employs serotonin-dopamine modulators to improve pro-social behavior. Solvonis also leverages an AI-supported discovery platform from a proprietary CNS library, initially targeting depression and stimulant use disorders, with recent expansions like SVN-015 into depression and U.S. patent allowances for PTSD innovations. Backed by experienced leadership including CEO Anthony Tennyson and Chief Scientific Advisor Prof. David Nutt, Solvonis employs a capital-efficient model to drive innovation in addiction, psychiatry, and emerging neurology areas. Incorporated in 2017, it plays a key role in addressing limited and ineffective current treatments for CNS disorders.
£0.00
+£0.00 (+5.00%)
EOD Jul 3, 2026
ROIC dropped from -46.32% to -60.41%, capital efficiency is deteriorating. Negative free cash flow of -£3M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
£0.00
Net Income (TTM)
-£6M
▼ -261.0% YoY
Op. Margin
—
ROIC
-60.41%
▼ -14.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-£3M
▼ -188.6% YoY
Op. Cash Flow (TTM)
-£3M
▼ -245.6% YoY
Net Debt
-£2M
Net Cash Position
Cash & Equiv.
£2M
Continue Research
Solvonis Therapeutics (SVNS.XLON)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Solvonis Therapeutics scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Solvonis Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -60.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh SVNS.XLON's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.